Sanofi Alleges Three Generic Drugmakers Infringe Three Patents on Heart Drug Multaq

Units of French drugmaker Sanofi Feb. 26 filed two complaints in the U.S. District Court for the District of Delaware against Glenmark Generics Inc. USA, Watson Laboratories Inc. and Actavis Inc. (the last two known as “Watson”) alleging infringement of patents related to its heart drug Multaq (Sanofi v. Glenmark Generics, Inc. USA; Sanofi v. Watson Labs, Inc.).

Watson notified Sanofi Jan. 16 that it had filed an abbreviated new drug application, with paragraph IV certification, with the Food and Drug Administration for approval of its generic version before the patents’ expiration, the complaint against Watson and ...